Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRV2: Comparative Immunogenicity of Respiratory Virus Vaccines
NCT07287137Phase 4Recruiting
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Start
- Nov 2025
- Primary completion
- Sep 2027
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of NVX-CoV2373 and tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine. Primary endpoint: Variant-specific immune responses (IgG binding antibody levels and neutralizing antibody titers) at 150 days. Started Nov 2025; status: recruiting.
02
Drugs
NVX-CoV2373tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07287137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287137.